We doubled our mammalian cell culture capacity in Europe!
Get More Info
About Us
Our Company
Executive Leadership
Locations
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Policies
COVID-19 Response
Environment, Health & Safety
Group Privacy Policies
Our Services
Offerings
Mammalian
Microbial
pDNA
Viral Vector
Cell Therapy
mRNA
Services
Tech Transfer
Process Development
Analytical Development
Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
News & Resources
Press Releases
Events
Thought Leadership
Resources
Case Studies
Fact Sheets
Video Library
Media Kit
Careers
Job Openings
Life at a CDMO
Diversity, Equity & Inclusion
Seattle Team
Boulder Team
Longmont Team
Copenhagen Team
Heidelberg Team
Milan Team
Chiba Team
Search
Search
Toggle Menu
Search
Search
Toggle Menu
About Us
Toggle Menu
Our Company
Executive Leadership
Locations
Toggle Menu
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Policies
Toggle Menu
COVID-19 Response
Environment, Health & Safety
Group Privacy Policies
Our Services
Toggle Menu
Offerings
Toggle Menu
Mammalian
Microbial
pDNA
Viral Vector
Cell Therapy
mRNA
Services
Toggle Menu
Tech Transfer
Process Development
Analytical Development
Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
News & Resources
Toggle Menu
Press Releases
Events
Thought Leadership
Resources
Toggle Menu
Case Studies
Fact Sheets
Video Library
Media Kit
Careers
Toggle Menu
Job Openings
Life at a CDMO
Diversity, Equity & Inclusion
Seattle Team
Boulder Team
Longmont Team
Copenhagen Team
Heidelberg Team
Milan Team
Chiba Team
Our Company
About Us
Our History
Mission & Values
Executive Leadership
Locations
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Policies
COVID-19 Policies
Environment, Health & Safety
Group Privacy Policies
Offerings
Mammalian
Microbial
pDNA
Viral Vector
Cell Therapy
mRNA
Services
Tech Transfer
Process Development
Analytical Development
Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
Fact Sheets
Global Manufacturing Capabilities (PDF)
CHEF1
TM
Expression Technology (PDF)
Analytical, Formulation and Stability (PDF)
Process Development (PDF)
Cell Therapy Capabilities (PDF)
Viral Vector Capabilities (PDF)
Plasmid DNA Capabilities (PDF)
Messenger RNA Capabilities (PDF)
News
Press Releases
Events
Thought Leadership
Resources
Case Studies
Fact Sheets
Video Library
Media Kit
Join Us
Career Opportunities
What Drives Us
Life at a CDMO
Diversity, Equity and Inclusion
Meet Our Teams
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Press Releases
Filter by Tag
All
Company News
Events
News
Partnership
News
2 min read
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
December 12, 2022 at 8:32 AM
News
Read More
1 min read
AGC Biologics Receives Excellence in Innovation and Leadership by Le Fonti Business News in Italy
December 1, 2022 at 6:45 AM
News
Read More
1 min read
AGC Biologics Honored for Innovations in Cell Line Development
October 13, 2022 at 7:46 AM
News
Read More
2 min read
AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
September 7, 2022 at 2:30 PM
News
Read More
2 min read
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
August 16, 2022 at 8:00 AM
News
Read More
1 min read
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
July 27, 2022 at 6:00 AM
News
Read More
1 min read
AGC Biologics Named Manufacturing Company of the Year by American Business Awards
June 29, 2022 at 6:00 AM
News
Read More
1 min read
AGC Biologics Provides Aid to Ukraine
May 11, 2022 at 2:01 PM
News
Read More
1 min read
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
March 31, 2022 at 6:00 AM
News
Read More
1 min read
AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material
February 8, 2022 at 4:00 PM
News
Company News
Partnership
Read More
1
2
3
4
5
Next
